Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

1.170 -0.050 (-4.10%)
Streaming Delayed Price Updated: 3:49 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cns Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Study Looks into Why Deadly Brain Tumors Continue to Grow After Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin
Via Investor Brand Network
Targeted Cancer Vaccines Show Promise in Halting Tumor Progression
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update
Via Investor Brand Network
Exposures Product Safety
Study Suggests That Test of Memory May Signal Brain Tumor Presence
Via Investor Brand Network
Symptoms of Brain Tumors To Watch For
Via Investor Brand Network
Researchers Want to Manage Cancer By Keeping Malignant Cells Restricted in Place
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success
Via Investor Brand Network
Exposures Product Safety
Study Finds That Ketogenic Diet May Help Patients with Brain Cancer
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advances Drug Candidate to Fight Aggressive Brain Cancer Amid Difficult Era for Market
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment
Via Investor Brand Network
Researchers Develop Blood Test to Improve Tumor Diagnosis, Monitoring
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Urges Shareholders to Vote in Favor of Proxy Proposals for Upcoming Annual Meeting
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial
Via Investor Brand Network
Preclinical Study Uncovers Potential Key to Treating Deadly Brain Tumors
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expands Patient Eligibility for Brain Cancer Drug Trial, Receives Approval from U.S. FDA for Protocol Amendment
Via Investor Brand Network
Exposures Product Safety
AI May Help Improve Brain Cancer Diagnosis
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures FDA Approval for Protocol Amendment to Ongoing Potentially Pivotal Berubicin Trial
Via Investor Brand Network
Exposures Product Safety
Study Suggests Healthcare Workers Don’t Know Enough About Childhood Brain Tumors
Via Investor Brand Network
Study Finds That Brain Tumors May Originate from Different Site
Via Investor Brand Network
Exposure to Wildfires Amplifies Cancer Risk, New Study Finds
Via Investor Brand Network
Genomic Sequencing Offers Hope in Diagnosis, Treatment of Brain Tumors
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Among Most Powerful of Chemotherapy Drugs
Via Investor Brand Network
Lantern Pharma to Host Glioblastoma Multiforme Webinar to Mark Brain Tumor Awareness Month
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract to be Presented at American Society of Clinical Oncology 2022 Annual Meeting
Via Investor Brand Network
Updated Guidelines Shed Light on Using Radiation Against Brain Metastases
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2022 Financial, Corporate Update
Via Investor Brand Network
Exposures Product Safety
Researchers Develop Models to Better Understand Brain Cancer Metastasis
Via Investor Brand Network
Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.